These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 20855960

  • 1. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P.
    Cancer Biol Ther; 2010 Nov 01; 10(9):903-17. PubMed ID: 20855960
    [Abstract] [Full Text] [Related]

  • 2. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.
    Cancer Res; 2012 Aug 15; 72(16):4225-37. PubMed ID: 22693249
    [Abstract] [Full Text] [Related]

  • 3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
    Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P.
    Cancer Biol Ther; 2009 Nov 15; 8(21):2084-96. PubMed ID: 19823038
    [Abstract] [Full Text] [Related]

  • 5. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
    Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P.
    Mol Pharmacol; 2012 May 15; 81(5):748-58. PubMed ID: 22357666
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
    Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P.
    Cancer Biol Ther; 2013 Oct 01; 14(10):982-96. PubMed ID: 24025251
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
    Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P.
    Mol Pharmacol; 2008 Sep 01; 74(3):807-22. PubMed ID: 18544666
    [Abstract] [Full Text] [Related]

  • 10. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L, Roberts JL, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.
    Cancer Biol Ther; 2018 Mar 04; 19(3):239-247. PubMed ID: 29333953
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
    Miller AV, Hicks MA, Nakajima W, Richardson AC, Windle JJ, Harada H.
    PLoS One; 2013 Mar 04; 8(4):e60685. PubMed ID: 23577147
    [Abstract] [Full Text] [Related]

  • 12. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
    Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P.
    Mol Pharmacol; 2012 Dec 04; 82(6):1217-29. PubMed ID: 22989520
    [Abstract] [Full Text] [Related]

  • 13. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC.
    Proc Natl Acad Sci U S A; 2007 Dec 04; 104(49):19512-7. PubMed ID: 18040043
    [Abstract] [Full Text] [Related]

  • 14. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
    Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P.
    Mol Pharmacol; 2012 Apr 04; 81(4):527-40. PubMed ID: 22219388
    [Abstract] [Full Text] [Related]

  • 15. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
    Nguyen M, Cencic R, Ertel F, Bernier C, Pelletier J, Roulston A, Silvius JR, Shore GC.
    BMC Cancer; 2015 Aug 01; 15():568. PubMed ID: 26231047
    [Abstract] [Full Text] [Related]

  • 16. OSU-03012 interacts with lapatinib to kill brain cancer cells.
    Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P.
    Cancer Biol Ther; 2012 Dec 01; 13(14):1501-11. PubMed ID: 22990204
    [Abstract] [Full Text] [Related]

  • 17. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S, Okumura K, Sinicrope FA.
    Clin Cancer Res; 2009 Jan 01; 15(1):150-9. PubMed ID: 19118042
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Blood; 2012 Jun 21; 119(25):6089-98. PubMed ID: 22446485
    [Abstract] [Full Text] [Related]

  • 19. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
    Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD.
    Neoplasia; 2009 Sep 21; 11(9):945-55. PubMed ID: 19724688
    [Abstract] [Full Text] [Related]

  • 20. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
    McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, O'Hagan B, Odrzywol K, Murray J, Longley D, McKerr G, Fennell DA.
    Cell Death Dis; 2010 Dec 16; 1(12):e108. PubMed ID: 21368880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.